TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
RDY

Dr. Reddy’s Laboratories Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

12.30$ +0.0% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Income Statement

Dr. Reddy’s Laboratories Ltd (RDY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 81,184 million INR. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size % Per share
Last 12 Full history
Download as CSV

All figures in millions of INR.

Tick rows to compare them in a chart (up to 4)

Income Statement RDY
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
35,857 37,065 35,542 33,159 35,460 38,060 35,349 37,207 37,978 38,500 40,166 38,435 48,009 43,838 44,318 44,175 658 49,296 649 49,194 778 53,197 723 52,154 790 67,700 766 67,384 832 72,148 70,830 76,727 80,162 83,586 85,060 85,452 88,051 87,268 76,331 81,184 332,834
15,760 15,166 17,360 16,062 16,559 16,649 16,454 16,479 17,081 17,748 19,113 18,576 20,389 20,116 21,510 19,420 326 22,758 301 23,495 362 24,585 341 26,148 323 27,607 328 27,831 363 29,945 29,347 30,383 32,393 34,534 37,797 36,825 39,911 40,462 42,116 43,421 165,910
20,097 21,899 18,182 17,097 18,901 21,411 18,895 20,728 20,897 20,752 21,053 19,859 27,620 23,722 22,808 24,755 332 26,538 348 25,699 416 28,612 382 26,006 467 40,093 438 39,553 469 42,203 41,483 46,344 47,769 49,052 47,263 48,627 48,140 46,806 34,215 37,763 166,924
5,214 4,956 4,579 5,075 4,175 4,667 4,348 4,157 4,120 3,668 3,662 3,609 3,662 3,949 4,190 3,980 55 4,108 56 4,534 60 4,159 57 4,325 61 4,821 65 4,984 66 5,565 6,877 6,193 7,271 6,658 7,258 6,244 6,202 6,149 5,548 5,800 23,699
246 198 253 249 204 247 183 176 170 0.0 11,225 10,918 15,440 11,467 11,023 13,107 13,107 14,387 14,279 15,045 15,951 15,411 15,674 15,493 16,560 17,981 12,760 17,702 28,858 20,228 20,476 22,691 23,007 24,117 24,055 23,181 26,436 15,885 14,468 26,096 82,885
16,709 16,128 15,047 16,640 15,099 16,402 16,248 16,028 16,323 15,023 15,708 11,920 20,318 16,391 16,199 16,647 211 18,367 253 19,121 276 19,355 266 13,815 269 23,602 284 21,917 293 25,297 26,524 28,419 30,218 30,332 29,616 31,152 30,627 32,568 33,742 34,791 131,728
3,386 5,789 3,135 453 3,808 5,009 2,647 4,768 5,046 5,729 5,345 7,944 7,316 -5,869 6,602 8,107 121 2,199 95 6,607 140 9,235 116 12,212 198 16,425 154 17,636 176 17,267 14,959 17,925 17,551 18,720 17,647 17,475 17,513 14,238 473 2,972 35,196
126 164 196 215 223 172 1,032 2.9 208 515 245 297 4.3 152 230 233 252 188 297 193 234 215 316 347 309 419 354 4.5 353 394 593 598 757 818 656 830 907 952 1,073 1,262 4,195
3,835 5,922 3,189 772 3,876 5,945 3,748 5,007 5,780 5,805 5,851 8,500 7,664 -5,274 7,142 8,789 116 2,843 85 7,425 171 9,709 33 14,655 202 16,346 161 18,463 231 18,257 16,016 18,821 19,167 18,742 20,054 19,047 18,350 15,429 2,022 5,559 41,360
885 1,221 64 181 1,027 2,601 726 446 742 953 1,507 1,872 -3,261 423 -500 2,996 13 2,645 35 1,717 37 2,644 21 2,779 62 3,875 45 4,438 52 4,468 2,946 4,901 5,752 4,704 4,182 4,951 4,082 3,533 -217 1,185 8,583
2,950 4,701 3,125 591 2,849 3,344 3,022 4,561 5,038 4,852 4,344 6,628 10,925 -5,697 7,642 5,793 102 198 50 5,708 134 7,065 12 11,876 139 12,471 117 14,025 179 13,789 13,070 13,920 12,553 14,133 15,938 14,178 14,372 12,098 2,235 4,461 33,167
6,235 8,862 6,487 3,252 6,743 5,009 5,645 7,751 8,986 6,320 8,446 11,880 11,307 8,078 10,337 12,162 162 9,003 130 10,523 211 12,900 75 18,052 243 19,247 203 21,208 281 21,286 20,322 21,757 23,899 24,279 25,264 24,642 24,308 19,560 8,758 2,972 55,598

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?